Search

Pivotal Ruxolitinib Data Shows Promise for Patients with PV.

 

Polycythemia vera (PV) is a chronic, incurable blood cancer with limited treatment options. If uncontrolled, PV can cause serious cardiovascular complications, such as stroke and heart attack.

Read more

HemaSphere, the Official Journal of the European Hematology Association, Receives Its First Impact Factor

The Hague, June 2022 - HemaSphere, the official peer-reviewed journal of the European Hematology Association (EHA), has received its first Journal Impact Factor™. The preliminary 2021 Journal Impact Factor for HemaSphere is 8.

Read more

The past and future of the EU Blood, Tissues and Cells legislation

Photo credit: Ineke Oostveen

Blood, tissues and cells (BTC) are used in medicine and in hematology on a daily basis.

Read more

European Scientific foundation for Laboratory Hemato Oncology (ESLHO)

The objectives of ESLHO are to promote the continuous innovation and standardization of laboratory diagnostics focused on lymphoid malignancies, as well as to facilitate quality control and education in this field.

Read more

Revision of the EU’s pharmaceutical legislation

Background on the reformIn April 2023, the European Commission (EC) published two proposals to revise the existing (and outdated) pharmaceutical legislation. This includes legislation on medicines for children and rare diseases.

Read more

EHA European Hematology Exam 2018 Report

1. Method
a. Format
The second European Hematology Exam took place on Wednesday, June 13 in Stockholm, Sweden, and Bern, Switzerland. The Exam consisted of 100 multiple choice questions, covering all eight sections of the European Hematology Curriculum.

Read more